Jan 17 |
Allakos extends losses as analysts downgrade on Phase 2 setback
|
Jan 17 |
ELAB, KIND and RLX among pre-market losers
|
Jan 17 |
Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday
|
Jan 16 |
Crude Oil Edges Lower; Morgan Stanley Posts Upbeat Revenue
|
Jan 16 |
Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?
|
Jan 16 |
Allakos crashes on restructuring plans
|
Jan 16 |
UPDATE 2-Allakos tumbles after skin disease drug fails mid-stage studies
|
Jan 16 |
Allakos Announces a Restructuring to Focus on Development of AK006
|
Jan 16 |
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
|
Jan 16 |
Allakos to lay off half of staff, scrap drug after study setback
|